Zenas BioPharma, Inc.
NASDAQ:ZBIOBiotechnology
+$0.64 today
- Market cap
- $1.79B
- Beta
- -0.69
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$7.64
Volume 0.48M
Average 0.71M
ZBIO Total Non-current Assets
All assets not expected to be converted to cash within one year.
Zenas BioPharma, Inc.NASDAQ: ZBIO
Total Non-current Assets · Q1 FY2026 · quarter ended Mar 2026
Total non-current assets rises 9.8% from a year ago
Total non-current assets stood at $17.52M at the end of Q1 FY2026, up 9.8% from a year earlier and down 46.0% from the prior quarter. Over 3 fiscal years it compounded at +74.3% a year.
Context
- Total non-current assets amounted to 2.3% of total assets at the end of Q1 FY2026, down 2.4 pp from a year earlier.
- Total non-current assets increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current assets keeps rising in the next quarterly balance sheet after a +9.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 32.47M USD
- Year-over-year change
- +131.2%
- 3-year CAGR
- +74.3%
| Period | Period end | Total Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 32.47M | +131.2% |
| FY2024 | 2024-12-31 | 14.05M | +67.7% |
| FY2023 | 2023-12-31 | 8.38M | +36.5% |
| FY2022 | 2022-12-31 | 6.14M | — |
Total Non-current Assets vs competitors
How ZBIO compares with its peers on the latest reported figures
- ZBIO's Mar 2026 total non-current assets of $17.52M is the 3rd highest of the 8 companies compared; the peer median is $2.94M.
- Its year-over-year change of +9.8% is the highest of 7, against a peer median of -23.8%.
- Total non-current assets amounts to 2.3% of total assets for ZBIO, versus a peer median of 10.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $88.49M | -0.9% | -26.6% | 44.5% | |
| Mar 2026 | $34.62M | -0.7% | -1.5% | 13.2% | |
| Mar 2026 | $17.52M | +9.8% | +74.3% | 2.3% | |
| Mar 2026 | $6.47M | -38.0% | -23.3% | 10.2% | |
| Dec 2025 | $2.94M | -22.1% | +10.3% | 25.6% | |
UPBUpstream Bio, Inc. | Mar 2026 | $1.78M | -25.5% | +126.0% | 0.6% |
TRAXFirst Tracks Biotherapeutics Inc | Mar 2026 | $1.17M | — | — | 0.4% |
| Sep 2026 | $921K | -90.2% | +79.8% | 0.1% | |
| Peer median (excluding ZBIO) | $2.94M | -23.8% | +4.4% | 10.2% | |
Competitors are the stored peer set for ZBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Zenas BioPharma, Inc.
NASDAQ:ZBIO
Intrinsic Alpha fair value
Locked
Current Price
$26.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.